793 results match your criteria CNS Melanoma


Prediction of Immune-Checkpoint Blockade Monotherapy Response in Patients With Melanoma Based on Easily Accessible Clinical Indicators.

Front Oncol 2021 27;11:659754. Epub 2021 May 27.

Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.

Background: Immune checkpoint blocker (ICB) has shown significant clinical activity in melanoma. However, there are no clinically approved biomarkers to aid patient selection. We aimed to identify patients with advanced or metastatic melanoma who are likely to benefit from ICB monotherapy using easily accessible clinical indicators. Read More

View Article and Full-Text PDF

Intradural Extramedullary Primary Central Nervous System Melanoma of the Craniovertebral Junction during Pregnancy: Observations and Outcomes.

Surg Neurol Int 2021 3;12:198. Epub 2021 May 3.

Department of Surgery, University of Texas Rio Grande Valley, Edinburg, Texas, United States.

Background: Primary central nervous system (CNS) melanoma is a rare lesion derived from neural crest precursors. While its management is analogous to metastatic spinal melanoma, the literature does not describe this entity clearly in pregnant patients and the unique implications it presents. Here, we describe the case of a pregnant patient who presented with primary CNS melanoma of the cervical spine. Read More

View Article and Full-Text PDF

Patterns and trends of cancer incidence in children and adolescents in China, 2011-2015: A population-based cancer registry study.

Cancer Med 2021 Jun 2. Epub 2021 Jun 2.

Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Background: Cancer is a major concern for children and adolescents worldwide. This study aims to report on cancer incidence patterns at age 0-19 years in 2011-2015 and their trends in 2000-2015.

Methods: We collected data on malignancies in population of 0-19 years submitted by high-quality population-based cancer registries in China. Read More

View Article and Full-Text PDF

Synthesis and Anticancer Activity Evaluation of 5-[2-Chloro-3-(4-nitrophenyl)-2-propenylidene]-4-thiazolidinones.

Molecules 2021 May 20;26(10). Epub 2021 May 20.

Department of Pharmaceutical, Organic and Bioorganic Chemistry, Danylo Halytsky Lviv National Medical University, Pekarska 69, 79010 Lviv, Ukraine.

A series of novel 5-[(,2)-2-chloro-3-(4-nitrophenyl)-2-propenylidene]-thiazolidinones (Ciminalum-thiazolidinone hybrid molecules) have been synthesized. Anticancer activity screening toward the NCI60 cell lines panel, gastric cancer (AGS), human colon cancer (DLD-1), and breast cancer (MCF-7 and MDA-MB-231) cell lines allowed the identification of 3-{5-[(,2)-2-chloro-3-(4-nitrophenyl)-2-propenylidene]-4-oxo-2-thioxothiazolidin-3-yl}propanoic acid () with the highest level of antimitotic activity with mean GI/TGI values of 1.57/13. Read More

View Article and Full-Text PDF

Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases.

Clin Cancer Res 2021 May 25. Epub 2021 May 25.

The Department of Tumor Biology, The Moffitt Cancer Center and Research Institute, Tampa, Florida.

Purpose: Melanoma brain metastases (MBM) and leptomeningeal melanoma metastases (LMM) are two different manifestations of melanoma CNS metastasis. Here, we used single-cell RNA sequencing (scRNA-seq) to define the immune landscape of MBM, LMM, and melanoma skin metastases.

Experimental Design: scRNA-seq was undertaken on 43 patient specimens, including 8 skin metastases, 14 MBM, and 19 serial LMM specimens. Read More

View Article and Full-Text PDF

Cryptic Biosynthesis of the Berkeleypenostatins from Coculture of Extremophilic sp.

J Nat Prod 2021 05 6;84(5):1656-1665. Epub 2021 May 6.

Coculture fermentation of and yielded berkeleypenostatins A-G (-) as well as the previously reported berkeleylactones A-H, the known macrolide A26771B, citrinin, and patulin. As was true with the berkeleylactones, there was no evidence of the berkeleypenostatins in either axenic culture. The structures were deduced from analyses of spectral data, and the absolute configuration of berkeleypenostatin A () was determined by single-crystal X-ray crystallography. Read More

View Article and Full-Text PDF

Case Report: Pseudomeningeosis and Demyelinating Metastasis-Like Lesions From Checkpoint Inhibitor Therapy in Malignant Melanoma.

Front Oncol 2021 15;11:637185. Epub 2021 Apr 15.

Department of Neurology, Division of Clinical Neurooncology, University Hospital Essen, Essen, Germany.

Immune checkpoint inhibitors (ICIs) have considerably expanded the effective treatment options for malignant melanoma. ICIs revert tumor-associated immunosuppression and potentiate T-cell mediated tumor clearance. Immune-related neurologic adverse events (irNAEs) manifest in the central (CNS) or peripheral nervous system (PNS) and most frequently present as encephalitis or myasthenia gravis respectively. Read More

View Article and Full-Text PDF

Paraneoplastic Neurological Syndromes and Beyond Emerging With the Introduction of Immune Checkpoint Inhibitor Cancer Immunotherapy.

Front Neurol 2021 9;12:642800. Epub 2021 Apr 9.

Departments of Neurology and Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN, United States.

Paraneoplastic neurological syndromes are more commonly seen with malignancies such as small cell lung cancer, thymoma, gynecological malignancies, and breast cancer as well as seminoma. With the introduction of immune checkpoint inhibitor (ICI) cancer immunotherapy we see an increase of autoimmune neurological complications in patients with malignancies not traditionally associated with paraneoplastic neurological syndromes, such as melanoma and renal cell carcinoma. Immune checkpoint inhibitors enhance antitumor immune responses resulting often in immune-related adverse effects that can affect any organ, including the central and peripheral nervous system, neuromuscular junction and muscle. Read More

View Article and Full-Text PDF

mTOR/EGFR/iNOS/MAP2K1/FGFR/TGFB1 Are Druggable Candidates for N-(2,4-Difluorophenyl)-2',4'-Difluoro-4-Hydroxybiphenyl-3-Carboxamide (NSC765598), With Consequent Anticancer Implications.

Front Oncol 2021 26;11:656738. Epub 2021 Mar 26.

PhD Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University and Academia Sinica, Taipei, Taiwan.

Background: The application of computational and multi-omics approaches has aided our understanding of carcinogenesis and the development of therapeutic strategies. NSC765598 is a novel small molecule derivative of salicylanilide. This study aims to investigate the ligand-protein interactions of NSC765598 with its potential targets and to evaluate its anticancer activities

Methods: We used multi-computational tools and clinical databases, respectively, to identify the potential drug target for NSC765598 and analyze the genetic profile and prognostic relevance of the targets in multiple cancers. Read More

View Article and Full-Text PDF

Anticancer potential of coumarin and its derivatives.

Mini Rev Med Chem 2021 Apr 5. Epub 2021 Apr 5.

Central Department of Chemistry, Tribhuvan University, Kirtipur, Kathmandu. Nepal.

Coumarins are found in higher plants like Rutaceae and Umbelliferae and essential oils of cinnamon bark, cassia leaf, and lavender oil. Coumarin compounds show different biological properties viz antimicrobial, antibacterial, antifungal, antioxidant, antitumor, anti-HIV, antihypertension, anticoagulant, anticancer, antiviral, anti-inflammatory, analgesics, antidiabetic, anti-depressive, and other bioactive properties. Coumarin and its derivatives possess anticancer activity against different types of cancers such as prostate, renal, breast, laryngeal, lung, colon, CNS, leukemia, malignant melanoma. Read More

View Article and Full-Text PDF

Immune Checkpoint Inhibitor-Related Adrenal Insufficiency.

Authors:
Grace Cherry

Semin Oncol Nurs 2021 Apr 28;37(2):151131. Epub 2021 Mar 28.

UCLA Health Melanoma Program, Los Angeles, CA. Electronic address:

Objective: It is an exciting time in oncology nursing as new treatments are continually emerging to improve oncological outcomes for people affected by cancer. Immunotherapy is one such innovation in contemporary oncology practice, but the side effects of its treatment can be life threatening. Oncology nurses must be educated in the early identification of life-threatening side effects, and deliver evidence-based interventions to manage consequences of therapy such as, immune checkpoint inhibitor-related adrenal insufficiency. Read More

View Article and Full-Text PDF

[Melanocytic Tumors].

No Shinkei Geka 2021 Mar;49(2):389-394

Department of Translational Research, Brain Research Institute, Niigata University.

Primary melanocytic neoplasms of the central nervous system(CNS)presumably arise from leptomeningeal melanocytes that are derived from the neural crest. Melanocytic neoplasms associated with neurocutaneous melanosis likely derive from melanocyte precursor cells that reach the CNS after somatic mutations, mostly, of the . They should be distinguished from other melanotic tumors involving the CNS, including metastatic melanoma and other primary tumors that undergo melanization, such as melanocytic schwannomas, medulloblastomas, paragangliomas, and various gliomas, because these lesions require different patient workups and therapy. Read More

View Article and Full-Text PDF

AIM2 controls microglial inflammation to prevent experimental autoimmune encephalomyelitis.

J Exp Med 2021 May;218(5)

Department of Immunology, Key Laboratory of Immunological Environment and Disease, State Key Laboratory of Reproductive Medicine, Center for Global Health, Nanjing Medical University, Nanjing, China.

The role of the PYHIN family member absent in melanoma 2 (AIM2), another important inflammasome sensor, in EAE remains unclear. In this study, we found that AIM2 negatively regulates the pathogenesis of EAE independent of inflammasome activation. AIM2 deficiency enhanced microglia activation and infiltration of peripheral immune cells into the CNS, thereby promoting neuroinflammation and demyelination during EAE. Read More

View Article and Full-Text PDF

Control and Toxicity in Melanoma Versus Other Brain Metastases in Response to Combined Radiosurgery and PD-(L)1 Immune Checkpoint Inhibition.

Adv Radiat Oncol 2021 Jan-Feb;6(1):100561. Epub 2020 Sep 16.

Department of Radiation Oncology, Department of Internal Medicine, University of Alabama at Birmingham, Birmingham, Alabama.

Purpose: Prior studies have mixed conclusions about the efficacy and central nervous system (CNS) toxicity profile of combining radiosurgery with anti-programed cell death 1 (PD-1) immune checkpoint inhibition (ICI) for brain metastases. This study evaluates the safety and efficacy of combined radiosurgery and anti-PD-1 ICI for melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC) brain metastases (BM).

Methods And Materials: Forty-one patients with 153 radiation naïve melanoma BM and 33 patients with 118 BM of NSCLC and RCC origin from 2014 through 2019 received radiosurgery and either anti PD-1 receptor inhibition or anti PD-L1 inhibition targeting the PD-1 ligand with less than 4 months separating either therapy. Read More

View Article and Full-Text PDF
September 2020

Neurologic Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review.

Neurology 2021 04 2;96(16):754-766. Epub 2021 Mar 2.

From the Clinical Neurology Unit (A.M., A.B., G.L.G., M.V., A.V.), Santa Maria Della Misericordia University Hospital; Department of Medicine (DAME) (A.M., G.L.G., M.V.), University of Udine Medical School, Italy; French Reference Center for Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis (S.M.-C., J.H., A.V.), Hospices Civils de Lyon, Hôpital Neurologique; Synatac Team (S.M.-C., J.H., A.V.), NeuroMyoGene Institute, INSERM U1217/CNRS UMR5310; and University Claude Bernard Lyon 1 (S.M.-C., J.H., A.V.), Université de Lyon, France.

Objective: To define the clinical characteristics, management, and outcome of neurologic immune-related adverse events (n-irAEs) of immune checkpoint inhibitors (ICIs).

Methods: Systematic review of the literature following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.

Results: A total of 694 articles were identified. Read More

View Article and Full-Text PDF

Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies.

Cancer 2021 Jun 2;127(12):2062-2073. Epub 2021 Mar 2.

Department of Neurosurgery and Brain Metastasis Center, Memorial Sloan Kettering Cancer Center, New York, New York.

Background: Historically, the prognosis for patients who have melanoma brain metastasis (MBM) has been dismal. However, breakthroughs in targeted and immunotherapies have improved long-term survival in those with advanced melanoma. Therefore, MBM presentation, prognosis, and the use of multimodality central nervous system (CNS)-directed treatment were reassessed. Read More

View Article and Full-Text PDF

COVID‑19 and SARS‑CoV‑2 host cell entry mediators: Expression profiling of TMRSS4 in health and disease.

Int J Mol Med 2021 04 2;47(4). Epub 2021 Mar 2.

Department of Life Sciences, College of Health, Medicine and Life Sciences, Brunel University London, Uxbridge UB8 3PH, UK.

Severe acute respiratory syndrome (SARS) coronavirus‑2 (SARS‑CoV‑2), the causative viral agent for the ongoing COVID‑19 pandemic, enters its host cells primarily via the binding of the SARS‑CoV‑2 spike (S) proteins to the angiotensin‑converting enzyme 2 (ACE2). A number of other cell entry mediators have also been identified, including neuropilin‑1 (NRP1) and transmembrane protease serine 2 (TMPRSS2). More recently, it has been demonstrated that transmembrane protease serine 4 (TMPRSS4) along with TMPRSS2 activate the SARS‑CoV‑2 S proteins, and enhance the viral infection of human small intestinal enterocytes. Read More

View Article and Full-Text PDF

Improved survival without increased toxicity with influenza vaccination in cancer patients treated with checkpoint inhibitors.

Oncoimmunology 2021 Feb 17;10(1):1886725. Epub 2021 Feb 17.

Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden.

In international guidelines, influenza vaccination is recommended to cancer patients receiving antitumor treatment. Whether this recommendation should include patients treated with the recently introduced and now widely used checkpoint inhibitors (CPIs) is unclear. The immune hyperactivation after vaccination in a patient on CPI treatment may strengthen the antitumor immunity and improve patients´ prognosis. Read More

View Article and Full-Text PDF
February 2021

Detect it so you can treat it: A case series and proposed checklist to detect neurotoxicity in checkpoint therapy.

eNeurologicalSci 2021 Mar 1;22:100324. Epub 2021 Feb 1.

Department of Neurology, Essen University Hospital, Hufelandstrasse 55, 45147 Essen, Germany.

Background: Checkpoint inhibitors show impressive and durable responses in various cancer types and provide new avenues for cancer immunotherapy. However, these drugs have a variety of adverse events. Common autoimmune-related adverse effects include fatigue, hepatitis, skin rash, endocrine deficiencies, and colitis. Read More

View Article and Full-Text PDF

Ultrastructural and clinical features of central nervous system melanoma:Analysis of nine cases.

Ultrastruct Pathol 2021 Jan 15;45(1):79-89. Epub 2021 Feb 15.

Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.

To investigate the ultrastructural and clinical characteristics of melanoma of the central nervous system (CNS). The clinical and electron microscopy pathology data of nine patients with melanoma surveyed from 1993 to 2017 were analyzed. All the CNS melanomas were confirmed by transmission electron microscopy (TEM), including eight cases of primary melanomas and one case of metastatic melanoma. Read More

View Article and Full-Text PDF
January 2021

A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease.

J Vis Exp 2021 01 29(167). Epub 2021 Jan 29.

Department of Neuro-Oncology, H. Lee Moffitt Cancer Center & Research Institute; Department of Tumor Biology, H. Lee Moffitt Cancer Center & Research Institute;

Leptomeningeal disease (LMD) is an uncommon type of central nervous system (CNS) metastasis to the cerebral spinal fluid (CSF). The most common cancers that cause LMD are breast and lung cancers and melanoma. Patients diagnosed with LMD have a very poor prognosis and generally survive for only a few weeks or months. Read More

View Article and Full-Text PDF
January 2021

Incidence and real-world burden of brain metastases from solid tumors and hematologic malignancies in Ontario: a population-based study.

Neurooncol Adv 2021 Jan-Dec;3(1):vdaa178. Epub 2020 Dec 22.

Ontario Health (Cancer Care Ontario), Toronto, Ontario, Canada.

Background: Although intracranial metastatic disease (IMD) is a frequent complication of cancer, most cancer registries do not capture these cases. Consequently, a data-gap exists, which thwarts system-level quality improvement efforts. The purpose of this investigation was to determine the real-world burden of IMD. Read More

View Article and Full-Text PDF
December 2020

Improved survival in several cancers with use of H-antihistamines desloratadine and loratadine.

Transl Oncol 2021 Apr 5;14(4):101029. Epub 2021 Feb 5.

Department of Cancer Epidemiology, Clinical Sciences, Lund University, Lund, Sweden; Department of Oncology and Pathology, Clinical Sciences, Lund University, Lund, Sweden.

Background: We have previously shown an association with substantially improved survival in breast cancer and melanoma for desloratadine and loratadine users, and set out to find whether an improved survival can be seen in tumors with and without a known response to immune checkpoint therapy, such as anti-CTLA-4 or anti-PD-1.

Methods: We investigated survival and use of six common H-antihistamines (cetirizine, clemastine, desloratadine, ebastine, fexofenadine and loratadine) in a nation-wide cohort of all 429,198 Swedish patients with ten types of immunogenic (gastric, colorectal/anal, pancreatic, lung, breast, prostate, kidney, and bladder cancer, melanoma and Hodgkin lymphoma) and six non-immunogenic (liver, uterine, ovarian, brain/CNS, and thyroid cancer and non-Hodgkin lymphoma) tumors diagnosed 2006-2017. Follow-up was until 2019-02-24. Read More

View Article and Full-Text PDF

Lin28A/ oncogenic circuit is a potential therapeutic target in neurocutaneous melanosis-associated CNS tumors in children.

Neurooncol Adv 2021 Jan-Dec;3(1):vdaa174. Epub 2020 Dec 9.

Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

View Article and Full-Text PDF
December 2020

Clinical correlates for immune checkpoint therapy: significance for CNS malignancies.

Neurooncol Adv 2021 Jan-Dec;3(1):vdaa161. Epub 2020 Nov 27.

Neuro-Oncology Branch, CCR, NCI, National Institutes of Health, Bethesda, Maryland, USA.

Immune checkpoint inhibitors (ICIs) have revolutionized the field of cancer immunotherapy. Most commonly, inhibitors of PD-1 and CTLA4 are used having received approval for the treatment of many cancers like melanoma, non-small-cell lung carcinoma, and leukemia. In contrast, to date, clinical studies conducted in patients with CNS malignancies have not demonstrated promising results. Read More

View Article and Full-Text PDF
November 2020

Development and therapeutic potential of 2-aminothiazole derivatives in anticancer drug discovery.

Med Chem Res 2021 Jan 15:1-36. Epub 2021 Jan 15.

Department of Medicinal Chemistry and Pharmaceutical Sciences Research Center, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.

Currently, the development of anticancer drug resistance is significantly restricted the clinical efficacy of the most commonly prescribed anticancer drug. Malignant disease is widely prevalent and considered to be the major challenges of this century, which concerns the medical community all over the world. Consequently, investigating small molecule antitumor agents, which could decrease drug resistance and reduce unpleasant side effect is more desirable. Read More

View Article and Full-Text PDF
January 2021

Melanoma brain metastases: Biological basis and novel therapeutic strategies.

Exp Dermatol 2021 Jan 17. Epub 2021 Jan 17.

The Department of Tumor Biology, The Moffitt Cancer Center & Research Institute, Tampa, FL, USA.

The development of brain metastases is the deadliest complication of advanced melanoma and has long been associated with a dismal prognosis. The recent years have seen incredible progress in the development of therapies for melanoma brain metastases (MBM), with both targeted therapies (the BRAF-MEK inhibitor combination) and immune checkpoint inhibitors (the anti-CTLA-4, anti-PD-1 combination) showing impressive levels of activity. Despite this, durations of response for these therapies remain lower at intracranial sites of metastasis compared to extracranial metastases and it has been suggested that there are unique features of the brain microenvironment that contribute to therapeutic escape. Read More

View Article and Full-Text PDF
January 2021

Clinical Trials in Metastatic Uveal Melanoma: Current Status.

Ocul Oncol Pathol 2020 Dec 10;6(6):381-387. Epub 2020 Sep 10.

Department of Ophthalmic Oncology, Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.

Background: Uveal melanoma is a rare subtype of melanoma. Prognosis and survival rates for patients with metastatic uveal melanoma remain poor. No current FDA-approved standard of care therapy is available for patients with metastatic uveal melanoma. Read More

View Article and Full-Text PDF
December 2020

Fatal GNAQ-mutated CNS melanoma in an adolescent with nevus of Ota.

Pediatr Dermatol 2021 Mar 9;38(2):497-499. Epub 2021 Jan 9.

Department of Dermatology, Massachusetts General Hospital, Boston, MA, USA.

Nevus of Ota is an uncommon benign mesodermal melanosis that involves the first and second divisions of the trigeminal nerve. Primary non-cutaneous melanoma often involves distinct genetic mutations compared to cutaneous melanoma. In primary central nervous system (CNS) melanomas associated with nevus of Ota, somatic mutations most commonly occur at the Q209 and R183 residues of GNAQ and likely induce tumorigenesis through upregulation of the MAP kinase pathway. Read More

View Article and Full-Text PDF

[Clinical and microbiological characteristics of bloodstream infections in adult neutropenic patients].

Rev Argent Microbiol 2020 Dec 30. Epub 2020 Dec 30.

Servicio de Clínica Médica, Hospital Privado Universitario de Córdoba, Córdoba, Argentina; Instituto Universitario de Ciencias Biomédicas de Córdoba, Córdoba, Argentina. Electronic address:

Bloodstream infections (BI) are relevant in neutropenic patients because they are associated with an increased number of complications and death. The objective was determinate the epidemiologic and microbiologic features of the BI in neutropenic patients with solid neoplasm (SN) and hematologic neoplasm (HN). Retrospective study in two third level hospitals between 2009 and 2016. Read More

View Article and Full-Text PDF
December 2020